Applicability and impact of the COMPASS trial in a Canadian population of patients with atherosclerotic disease

In the COMPASS trial, low-dose rivaroxaban with aspirin improved cardiovascular outcomes in patients with atherosclerotic cardiovascular disease (ASCVD). We aimed to assess the potential clinical implications of this therapy in a generalizable population.

Source: Atherosclerosis - March 15, 2024 Category: Cardiology Authors: Robert C. Welsh, Pishoy Gouda, Doug Dover, Kevin R. Bainey, Finlay A. McAlister, Padma Kaul Source Type: research